Multiple sclerosis therapeutic pipeline: opportunities and challenges

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• The year 2010 heralded a new era in multiple sclerosis (MS) management with the advent of oral therapies.
• Fingolimod became the first oral disease-modifying agent, alongside dalfampridine for walking improvement.

Purpose of the Study:

• To review emerging oral and biologic therapies for multiple sclerosis.
• To discuss the opportunities and challenges presented by these new treatment paradigms.
• To highlight the need for personalized and interdisciplinary approaches in MS care.

Main Methods:

• Literature review of emerging multiple sclerosis therapeutics.
• Analysis of oral agents (cladribine, teriflunomide, laquinimod, dimethyl fumarate) and monoclonal antibodies (alemtuzumab, daclizumab, rituximab).
• Discussion of potential side effects, adverse event monitoring, and treatment strategies.

Main Results:

• Multiple sclerosis therapeutics in late-stage development include non-selective immunosuppressants, targeted immunomodulators, and monoclonal antibodies.
• Emerging oral agents and monoclonal antibodies offer new treatment avenues for multiple sclerosis.
• Potential side effects necessitate careful monitoring for infections, malignancies, and systemic consequences.

Conclusions:

• The expanding multiple sclerosis armamentarium requires multifactorial decision-making for patient selection and personalized therapy.
• Optimal staging, sequencing, and combination of treatments are critical challenges.
• A new generation of agents necessitates an increasingly interdisciplinary approach to multiple sclerosis management.